Annual Drug Patent Expirations for OFIRMEV
Ofirmev is a drug marketed by Mallinckrodt Hosp and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for OFIRMEV.
This drug has four patent family members in three countries.
The generic ingredient in OFIRMEV is acetaminophen. Two suppliers are listed for this compound. Additional details are available on the acetaminophen profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com